The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
While overall survival data remain immature, the results pointed to a favourable trend.
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
Subscribe To Our Newsletter & Stay Updated
